SCHEMBL1765978

SCHEMBL1765978

CC(C)c1oc(-c2ccc(Cl)cc2Cl)nc1CCC(=O)c1ccc(OC(C)(C)C(=O)O)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 13/20 0.61
PPARD Q03181 11/20 0.61
PPARG P37231 10/20 0.61
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36
SHMT1 P34896 1/20 0.35
SHMT2 P34897 1/20 0.35
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
S1PR5 Q9H228 1/20 0.34
TP53 P04637 1/20 0.34
DPP4 P27487 1/20 0.34
DPP7 Q9UHL4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463893 0.95 PPARD (0.60) PPARAPPARDPPARGHSD17B10SMN1; SMN2
SCHEMBL12732436 0.93 PPARA (0.53) PPARAPPARDPPARGHSD17B10SMN1; SMN2
SCHEMBL1765972 0.91 PPARA (0.69) PPARAPPARDPPARGSMN1; SMN2MAPT
SCHEMBL2463966 0.90 PPARA (0.51) PPARAPPARDPPARGHSD17B10SMN1; SMN2
SCHEMBL24742577 0.90 PPARA (0.51) PPARAPPARDPPARGHSD17B10SMN1; SMN2
SCHEMBL30003775 0.90 PPARA (0.51) PPARAPPARDPPARGHSD17B10SMN1; SMN2
SCHEMBL2466184 0.88 PPARD (0.52) PPARAPPARDPPARG
SCHEMBL377020 0.88 PPARA (0.66) PPARAPPARDPPARGHSD17B10SMN1; SMN2
SCHEMBL1765865 0.87 PPARA (0.62) PPARAPPARDPPARGSMN1; SMN2MAPT
SCHEMBL4754218 0.87 PPARA (0.49) PPARAPPARDPPARGHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190255022-A1 WOUND-HEALING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2019-08-22 US claimed
EP-3456327-A1 WOUND-HEALING AGENT Nippon Chemiphar Co., Ltd. (JP) 2019-03-20 EP claimed
US-7652045-B2 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) NIPPON CHEMIPHAR, CO., LTD. (JP) 2010-01-26 US claimed
US-20190255022-A1 WOUND-HEALING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2019-08-22 US disclosed
EP-3456327-A1 WOUND-HEALING AGENT Nippon Chemiphar Co., Ltd. (JP) 2019-03-20 EP disclosed
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
EP-1424330-B1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA NIPPON CHEMIPHAR CO (JP) 2011-09-28 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
US-7652045-B2 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) NIPPON CHEMIPHAR, CO., LTD. (JP) 2010-01-26 US disclosed
US-7648999-B2 Activator for peroxisome proliferator-activated receptor δ NIPPON CHEMIPHAR CO., LTD. (JP) 2010-01-19 US disclosed
WO-2008154023-A1 NOVEL USES OF PPAR DELTA AGONISTS CERENIS THERAPEUTICS S.A. (FR) 2008-12-18 WO disclosed
US-20080009525-A1 Activator of peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2008-01-10 US disclosed
US-20080009631-A1 Activator for peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2008-01-10 US disclosed
US-7265137-B2 Activator of peroxisome proliferator-activated re-ceptor δ NIPPON CHEMIPHAR CO., LTD. (JP) 2007-09-04 US disclosed
US-20050054674-A1 Activator of peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2005-03-10 US disclosed
EP-1424330-A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA NIPPON CHEMIPHAR CO., LTD. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009525-A1 Activator of peroxisome proliferator-activated receptor delta PPARG, PPARD, PPARA PPARA 3/4885PPARD 2/4885PPARG 1/4885
US-20190255022-A1 WOUND-HEALING AGENT PPARG, PPARA, PPARD PPARA 2/4885PPARD 3/4885PPARG 1/4885
US-20080009631-A1 Activator for peroxisome proliferator-activated receptor delta PPARG, PPARD, PPARA PPARA 3/4885PPARD 2/4885PPARG 1/4885
US-20050054674-A1 Activator of peroxisome proliferator-activated receptor PPARG, PPARD, PPARA PPARA 3/4885PPARD 2/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.